Reversing the Heart's Genetic Clock: Correcting PRKAG2 Mutations Using Prime Editing
##1. The Hidden Culprit of Hypertrophic Cardiomyopathy, PRKAG2 Mutation PRKAG2 syndrome is a rare inherited cardiomyopathy characterized by abnormal thickening of the heart muscle (hypertrophy), excessive glycogen accumulation, and life‑threatening arrhythmias. In particular, a single‑base missense mutation (c.2084A>G, p.His530Arg) disables the heart’s energy‑metabolism regulation, posing a serious threat to patients. To date, management of this disease has been limited to symptom control rather than fundamental gene correction.
##2. Prime Editing: Realizing Precise Gene Surgery The research team employed the latest gene‑editing tool, Prime Editing, which addresses limitations of conventional CRISPR approaches. Unlike earlier methods that randomly cleave DNA and carry a high risk of unwanted insertions or deletions (indels), Prime Editing precisely targets a specific genomic locus and restores only the intended nucleotide to its wild‑type state. Using this technology, the team successfully corrected the pathogenic mutation in patient‑derived induced pluripotent stem cells (iPSCs) without detectable off‑target effects.
##3. Construction of Isogenic iPSC Lines and Their Research Value The successfully corrected iPSCs constitute a valuable research resource known as an “isogenic line,” enabling direct comparison of the pre‑ and post‑mutation states. Because the lines share the same patient genetic background and differ only by the presence or absence of the disease‑causing PRKAG2 mutation, experimental variability is minimized. This provides the most reliable data source for elucidating disease mechanisms at the molecular level and for conducting large‑scale drug screening to develop bona‑fide therapeutics.
##4. A Leap Toward Precision Medicine for Conquering Genetic Diseases These findings offer patients with rare genetic disorders not merely symptomatic management but a potential cure. If the high safety and precision of Prime Editing are validated in clinical trials, a true era of precision medicine—where the root cause of hypertrophic cardiomyopathy and countless other genetic diseases can be directly repaired—will emerge. This represents a pivotal turning point that could reshape the life trajectories of individuals previously bound by genetic destiny.
PRKAG2 cardiac syndrome is a rare inherited cardiomyopathy characterized by clinical manifestations such as abnormal cardiac hypertrophy, glycogen storage, and arrhythmias. We derived two human induced pluripotent stem cell (iPSC) lines carrying a heterozygous PRKAG2 missense mutation (c.2084A>G, p.His530Arg) from two patients with hypertrophic cardiomyopathy. Using Prime Editing, we precisely corrected this mutation in patient-specific iPSCs. This approach enables a valuable resource for advancing precision medicine research in PRKAG2 cardiac syndrome.
This dataset demonstrates the accuracy of the cutting‑edge gene‑correction technology Prime Editing in a patient‑derived cellular model. Because it includes isogenic control data, it serves as a high‑quality source optimized for training AI‑based disease‑modeling and drug‑response prediction algorithms.